Abstract 64P
Background
Colo rectal cancer is the third most common cancer in the world. Clinical data on localized colon cancer and treatment outcome is scarce in the literature. This is a real-world study of the clinical profile and treatment patterns and outcomes of patients with nonmetastatic colon cancer from India. Here we report our experience in this patient population.
Methods
This is a retrospective chart review of patients with nonmetastatic colon cancer registered in our hospital from May 2011 to December 2021. Patients who presented with recurrent metastatic disease were included in this review if the treatment details for the localized disease were available. The baseline demographic features and treatment details and toxicity were recorded.
Results
Total of 1084 patients were registered during this time period. The median age of the population was 60 (9-91 )years. Males constituted 648 (60%) of cases. The most common site of the primary was descending and sigmoid colon (41%). Majority of the patients had stage III disease (46.5%). Most of our patients received capecitabine and oxaliplatin-based combination therapy. The median disease-free survival is 30.7 months.
Conclusions
Most common site of colon cancer is the left side and stage III is the most common stage of presentation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
129P - Chemoradiation in carcinoma esophagus with weekly paclitaxel ad carboplatin: A real-world experience from a tertiary care center
Presenter: Nidhi Sharma
Session: Poster viewing 02
130P - Radiation induced lymphopenia (RAILs on time saves nine): In carcinoma esophagus
Presenter: Sheel Mohanty
Session: Poster viewing 02
131TiP - ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
Presenter: Andrew Dean
Session: Poster viewing 02
134TiP - A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
Presenter: Hiroshi Imaoka
Session: Poster viewing 02